U.S. markets open in 2 hours 45 minutes
  • S&P Futures

    3,888.75
    +21.25 (+0.55%)
     
  • Dow Futures

    31,560.00
    +202.00 (+0.64%)
     
  • Nasdaq Futures

    13,139.75
    +84.50 (+0.65%)
     
  • Russell 2000 Futures

    2,253.30
    +24.20 (+1.09%)
     
  • Crude Oil

    60.88
    +1.13 (+1.89%)
     
  • Gold

    1,720.70
    -12.90 (-0.74%)
     
  • Silver

    26.63
    -0.25 (-0.93%)
     
  • EUR/USD

    1.2071
    -0.0016 (-0.13%)
     
  • 10-Yr Bond

    1.4150
    0.0000 (0.00%)
     
  • Vix

    22.91
    -0.44 (-1.88%)
     
  • GBP/USD

    1.3957
    +0.0000 (+0.00%)
     
  • USD/JPY

    106.9900
    +0.2800 (+0.26%)
     
  • BTC-USD

    51,246.45
    +2,081.68 (+4.23%)
     
  • CMC Crypto 200

    1,023.74
    +35.65 (+3.61%)
     
  • FTSE 100

    6,677.13
    +63.38 (+0.96%)
     
  • Nikkei 225

    29,559.10
    +150.93 (+0.51%)
     

LGND vs. TECH: Which Stock Should Value Investors Buy Now?

  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Ligand Pharmaceuticals (LGND) and Techne (TECH). But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.

Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.

Currently, Ligand Pharmaceuticals has a Zacks Rank of #2 (Buy), while Techne has a Zacks Rank of #3 (Hold). This means that LGND's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. But this is only part of the picture for value investors.

Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels.

The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.

LGND currently has a forward P/E ratio of 29.42, while TECH has a forward P/E of 61.36. We also note that LGND has a PEG ratio of 1.96. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. TECH currently has a PEG ratio of 10.23.

Another notable valuation metric for LGND is its P/B ratio of 2.32. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. By comparison, TECH has a P/B of 7.77.

Based on these metrics and many more, LGND holds a Value grade of A, while TECH has a Value grade of D.

LGND is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. And, based on the above valuation metrics, we feel that LGND is likely the superior value option right now.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report
 
BioTechne Corp (TECH) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research